BACKGROUND: Thermal ablation techniques have become important treatment options for patients with unresectable hepatic malignancies. Microwave ablation (MWA) is a new thermal ablative technique that uses electromagnetic energy to produce coagulation necrosis. We report outcomes from the first clinical trial in the United States using MWA and a 915 MHz generator. PATIENTS AND METHODS: Patients with unresectable primary or metastatic liver cancer were enrolled in a multi-institutional trial from March 2004 through May 2006. Demographic information, diagnosis, treatment, and outcomes were documented. RESULTS: Eighty-seven patients underwent 94 ablation procedures for 224 hepatic tumors. Forty-two ablations (45%) were performed open, 7 (7%) laparoscopically, and 45 (48%) percutaneously. The average tumor size was 3.6 cm (range 0.5-9.0 cm). Single antenna ablation volumes were 10.0 ml (range 7.8-14.0 ml), and clustered antennae ablation volumes were 50.5 ml (range 21.1-146.5 ml). Outcome variables were measured with a mean follow-up of 19 months. Local recurrence at the ablation site occurred in 6 (2.7%) tumors, and regional recurrence occurred in 37 (43%) patients. With a mean follow-up of 19 months, 41 (47%) patients were alive with no evidence of disease. There were no procedure-related deaths. The overall mortality rate was 2.3%. CONCLUSIONS: Microwave ablation is a safe and effective technology for hepatic tumor ablation. In our study, clustered antennae resulted in larger ablation volumes. Further studies with histological confirmation are needed to verify clinical results.
BACKGROUND: Thermal ablation techniques have become important treatment options for patients with unresectable hepatic malignancies. Microwave ablation (MWA) is a new thermal ablative technique that uses electromagnetic energy to produce coagulation necrosis. We report outcomes from the first clinical trial in the United States using MWA and a 915 MHz generator. PATIENTS AND METHODS: Patients with unresectable primary or metastatic liver cancer were enrolled in a multi-institutional trial from March 2004 through May 2006. Demographic information, diagnosis, treatment, and outcomes were documented. RESULTS: Eighty-seven patients underwent 94 ablation procedures for 224 hepatic tumors. Forty-two ablations (45%) were performed open, 7 (7%) laparoscopically, and 45 (48%) percutaneously. The average tumor size was 3.6 cm (range 0.5-9.0 cm). Single antenna ablation volumes were 10.0 ml (range 7.8-14.0 ml), and clustered antennae ablation volumes were 50.5 ml (range 21.1-146.5 ml). Outcome variables were measured with a mean follow-up of 19 months. Local recurrence at the ablation site occurred in 6 (2.7%) tumors, and regional recurrence occurred in 37 (43%) patients. With a mean follow-up of 19 months, 41 (47%) patients were alive with no evidence of disease. There were no procedure-related deaths. The overall mortality rate was 2.3%. CONCLUSIONS: Microwave ablation is a safe and effective technology for hepatic tumor ablation. In our study, clustered antennae resulted in larger ablation volumes. Further studies with histological confirmation are needed to verify clinical results.
Authors: Sarah A Shock; Kenneth Meredith; Thomas F Warner; Lisa A Sampson; Andrew S Wright; Thomas C Winter; David M Mahvi; Jason P Fine; Fred T Lee Journal: Radiology Date: 2004-04 Impact factor: 11.105
Authors: K Ohmoto; I Miyake; M Tsuduki; N Shibata; M Takesue; T Kunieda; S Ohno; M Kuboki; S Yamamoto Journal: Hepatogastroenterology Date: 1999 Sep-Oct
Authors: Meghan G Lubner; J Louis Hinshaw; Anita Andreano; Lisa Sampson; Fred T Lee; Christopher L Brace Journal: J Vasc Interv Radiol Date: 2012-01-24 Impact factor: 3.464
Authors: William W Hope; Jason M Arru; Jason Q McKee; Dennis Vrochides; Bassam Aswad; Caroline J Simon; Damian E Dupuy; David A Iannitti Journal: HPB (Oxford) Date: 2007 Impact factor: 3.647
Authors: Meghan G Lubner; Christopher L Brace; Tim J Ziemlewicz; J Louis Hinshaw; Fred T Lee Journal: Semin Intervent Radiol Date: 2013-03 Impact factor: 1.513
Authors: Ryan T Groeschl; Ray K Wong; Edward J Quebbeman; Susan Tsai; Kiran K Turaga; Sam G Pappas; Kathleen K Christians; Eric J Hohenwalter; Sean M Tutton; William S Rilling; T Clark Gamblin Journal: HPB (Oxford) Date: 2012-10-11 Impact factor: 3.647
Authors: Karin Nielsen; Aukje A J M van Tilborg; Martijn R Meijerink; Matessa O Macintosh; Babs M Zonderhuis; Elly S M de Lange; Emile F I Comans; Sybren Meijer; M Petrousjka van den Tol Journal: World J Surg Date: 2013-06 Impact factor: 3.352
Authors: Kerri A Simo; Victor B Tsirline; David Sindram; Matthew T McMillan; Kyle J Thompson; Ryan Z Swan; Iain H McKillop; John B Martinie; David A Iannitti Journal: HPB (Oxford) Date: 2013-03-14 Impact factor: 3.647